Following Lenz Therapeutics’ debut on the Nasdaq Friday, Endpoints News spoke with CEO Eef Schimmelpennink about the thinking behind choosing a reverse merger over an IPO and its upcoming Phase 3 results. In the next few weeks, Lenz is expected to report data from Phase 3 studies of its eye drops LNZ100 and LNZ101. It then plans to pick the better of the two to submit for approval as it plans to go up against AbbVie’s Vuity and Orasis Pharmaceuticals’ Qlosi, which was approved last October. Endpoints spoke with Schimmelpennink on the company’s first morning of trading, with the shares $LENZ up more than 10%.
Read the full article: Why Lenz Picked a Reverse Merger Instead of an IPO: Q&A //
Source: https://endpts.com/why-lenz-picked-a-reverse-merger-instead-of-an-ipo-qa/